BIB vs. BIS
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares UltraShort Nasdaq Biotechnology (BIS).
BIB and BIS are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. BIS is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (-200%). It was launched on Apr 7, 2010. Both BIB and BIS are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIB or BIS.
Key characteristics
| BIB | BIS | |
|---|---|---|
| YTD Return | -14.15% | 14.90% |
| 1Y Return | -9.79% | 4.67% |
| 3Y Return (Ann) | -19.07% | 1.53% |
| 5Y Return (Ann) | -0.71% | -21.55% |
| 10Y Return (Ann) | 3.37% | -25.09% |
| Sharpe Ratio | -0.37 | 0.23 |
| Daily Std Dev | 33.04% | 33.21% |
| Max Drawdown | -67.24% | -99.76% |
| Current Drawdown | -56.03% | -99.68% |
Correlation
The correlation between BIB and BIS is -0.95. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Performance
BIB vs. BIS - Performance Comparison
In the year-to-date period, BIB achieves a -14.15% return, which is significantly lower than BIS's 14.90% return. Over the past 10 years, BIB has outperformed BIS with an annualized return of 3.37%, while BIS has yielded a comparatively lower -25.09% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. BIS - Expense Ratio Comparison
Both BIB and BIS have an expense ratio of 0.95%.
Risk-Adjusted Performance
BIB vs. BIS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares UltraShort Nasdaq Biotechnology (BIS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIB vs. BIS - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.16%, less than BIS's 2.31% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.16% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% |
BIS ProShares UltraShort Nasdaq Biotechnology | 2.31% | 1.75% | 0.00% | 0.00% | 0.44% | 2.11% | 0.37% |
Drawdowns
BIB vs. BIS - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum BIS drawdown of -99.76%. Use the drawdown chart below to compare losses from any high point for BIB and BIS. For additional features, visit the drawdowns tool.
Volatility
BIB vs. BIS - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares UltraShort Nasdaq Biotechnology (BIS) have volatilities of 10.00% and 9.85%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.